Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 8/16/2017 10:33:38 PM - Followers: 147 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#4884  Sticky Note AUPH: Now that Ph3 for LN is underway Lunacy aka John Galt 07/19/17 06:05:27 PM
#5226   high integrity is something to be applauded and zzaatt 08/16/17 10:33:38 PM
#5225   Agree with your comment about integrity. Except, SantaFe Miguel 08/16/17 10:09:39 PM
#5224   ".....highly speculative stock as per the ceo....." moosedogger 08/16/17 08:00:27 PM
#5223   We know that Schwab and Fidelity have similar nsomniyak 08/16/17 05:03:36 PM
#5222   If Fido has it TDA has it as well. biotech_researcher 08/16/17 04:59:28 PM
#5221   this being a highly speculative stock as per cervelo 08/16/17 04:50:24 PM
#5220   I consider myself to be a principled investor, nsomniyak 08/16/17 04:39:45 PM
#5219   "FDA under fire over accelerated approval data demands" moosedogger 08/16/17 03:18:08 PM
#5218   Happy National Rum Day to all! rumrunner528 08/16/17 11:45:46 AM
#5217   Call your broker to better understand this program. biotech_researcher 08/16/17 09:49:57 AM
#5215   Yes I know but 20% ? I've never Easymoneyman00 08/16/17 09:25:21 AM
#5214   Of course it's going to happen we just Maciste 08/16/17 08:36:38 AM
#5213   SvsB, very valid point. Thank you. I would biotech_researcher 08/15/17 08:12:32 PM
#5212   It's called summer. SvsB 08/15/17 07:10:51 PM
#5211   Pathetic volume each day. This is an unknown biotech_researcher 08/15/17 03:39:46 PM
#5210   So far, the stock has survived a 2nd Zeppo 08/15/17 10:38:15 AM
#5207   Buying volume beats shorting and vise versa. It's Mr_Popeye 08/13/17 11:07:33 PM
#5206   All us principaled investors agree with your questioning. ThePromise247 08/13/17 02:16:38 PM
#5201   I like old reports - Leerink: "75% probability grandma_of_jbraika 08/12/17 10:56:48 AM
#5200   depending on the demand for shorting the stock. biotech_researcher 08/12/17 04:56:43 AM
#5199   Easy, you don't understand how the share lending biotech_researcher 08/12/17 04:43:38 AM
#5198   That level of aggressive response really is unwarranted. nsomniyak 08/12/17 12:55:50 AM
#5197   I am just reporting what Schwab has offered nsomniyak 08/12/17 12:49:13 AM
#5196   There is no single answer for that - nsomniyak 08/12/17 12:47:14 AM
#5195   What are you getting for our covered calls? Easymoneyman00 08/11/17 11:24:44 PM
#5194   That sounds very high interest on any shares. Easymoneyman00 08/11/17 11:23:19 PM
#5192   For a premium of what? .75% ? Easymoneyman00 08/11/17 11:17:13 PM
#5191   The securities lending program is interesting from many nsomniyak 08/11/17 06:37:27 PM
#5190   I assume you mean on AUPH - no, nsomniyak 08/11/17 06:32:33 PM
#5189   Did You lend all your shares minus Jesspro 08/11/17 06:27:53 PM
#5188   I would much rather lend my shares to nsomniyak 08/11/17 06:10:22 PM
#5187   I was just indicating that the securities lending nsomniyak 08/11/17 06:08:26 PM
#5186   Sounds like the Fidelity program is structured very nsomniyak 08/11/17 06:05:49 PM
#5185   nsomniyak, thank you for this info! I called biotech_researcher 08/11/17 05:20:13 PM
#5184   I'm glad you have made a few thousand. I'm Hotrodder1 08/11/17 04:41:41 PM
#5183   This is a classic short covering rally. They biotech_researcher 08/11/17 03:27:08 PM
#5182   I think that lending program is perfect for nsomniyak 08/11/17 03:25:07 PM
#5181   Yes, it seems like this is the perfect Jesspro 08/11/17 03:09:41 PM
#5180   No, I don't have a high limit sell Jesspro 08/11/17 03:00:15 PM
#5179   Schwab offered me 7.5% on my AUPH shares, nsomniyak 08/11/17 02:40:59 PM
#5178   Do you have a high limit sell order Lunacy aka John Galt 08/11/17 02:24:57 PM
#5177   Don't help the short drive away more retail holders wilco244 08/11/17 02:23:04 PM
#5176   Shorts are desperate. My broker just left a Jesspro 08/11/17 02:19:25 PM
#5175   I can live with that. If your prediction Jesspro 08/11/17 02:02:47 PM
#5174   By the way several years ago I said puravida 08/11/17 02:01:44 PM
#5173   That all sounds good to me...hopefully we get Lunacy aka John Galt 08/11/17 01:58:36 PM
#5172   I think they partner exclusively in the Asian puravida 08/11/17 01:51:02 PM
#5171   It could be sold early. It could be Jesspro 08/11/17 01:45:45 PM
#5170   Still here. Still holding all of my shares. puravida 08/11/17 01:37:11 PM
#5168   cervelo, I'm with youOf course you are!!! zzaatt 08/11/17 09:47:04 AM